Teladoc (TDOC) AI Stock Analysis

• Market Cap: $1.38B
• Dividend Yield: N/A
• Average Volume (3M): 7.41M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.38
• Revenue Growth: -2.54%
• EPS Growth: -322.03%
• Country: US
• Employees: 4,620
• Sector: Healthcare
• Sector Strength: 44
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.53
• Shares Outstanding: 175,434,770
• 10 Day Avg. Volume: 5,566,896
• 30 Day Avg. Volume: 7,414,999
• PEG Ratio: 2.00
• Price to Book (P/B): 0.97
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 6.63
• Enterprise Value/Market Cap: 1.29
• Enterprise Value/Revenue: 0.17
• Enterprise Value/Gross Profit: 1.05
• Enterprise Value/Ebitda: -0.72
• 1Y Price Target: $8.59
• Price Target Upside: 6.84% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 16

• Rating: 56 Neutral
• Price Target: $8.00 ▼(-0.50%Downside)

Teladoc's overall stock score reflects a balance of strategic growth initiatives and financial challenges. The company's focus on international expansion and new acquisitions provides potential for future growth, but current profitability issues and valuation concerns weigh heavily on the stock's attractiveness.

Positive Factors

Acquisitions

Teladoc's recent acquisitions, Catapult and Uplift, provide optionality to drive higher revenue per member.

Competitive Advantage

Teladoc's base of over 100 million US Integrated Care members provides a competitive advantage to cross-sell its broad and improving offerings.

Revenue Growth

International revenue is estimated to grow by 26%.

Negative Factors

Chronic Care Enrollment

Teladoc expects chronic care enrollment to decline sequentially due to a previously discussed contract loss.

Near-term Margins

Additional investments needed to optimize care delivery could drive weaker near-term margins.

User Metrics Decline

BetterHelp MAUs decelerate, and international MAUs decline year over year.

Teladoc Business Overview & Revenue Model

Company Description

Teladoc Health, Inc. (TDOC) is a global leader in virtual healthcare services, operating in the telemedicine and telehealth sectors. The company provides a broad spectrum of healthcare services, including on-demand remote medical care through mobile devices, the internet, video, and phone. Teladoc's core services encompass primary care, mental health support, dermatology, nutrition, and chronic condition management, aiming to provide convenient, affordable access to quality healthcare.

How the Company Makes Money

Teladoc generates revenue through a combination of subscription fees and visit fees. Subscription fees are primarily derived from contracts with employers, health plans, and insurance providers, who pay Teladoc to offer its services to their members or employees. These contracts are typically based on a per-member-per-month fee structure. Additionally, Teladoc earns visit fees each time a member uses its services for a medical consultation. The company also benefits from strategic partnerships with healthcare providers and insurers, which expand its reach and increase its client base. Other revenue streams include licensing its technology platform to other healthcare providers and offering specialty services that cater to specific medical needs.

Teladoc Financial Statement Overview

Summary

Teladoc's financial performance is marked by ongoing challenges in profitability, with negative net profit margins and fluctuating revenue growth. However, improvements in free cash flow and a stable equity base provide some positive outlooks.

Income Statement

Teladoc has shown fluctuating revenue growth, with a decline from 2023 to the TTM period. The gross profit margin is stable at around 66-67%, but the net profit margin remains negative, indicating ongoing losses. EBIT and EBITDA margins are also negative, reflecting operational challenges.

Balance Sheet

The debt-to-equity ratio is relatively high, suggesting considerable leverage, but the equity ratio demonstrates a stable equity base. The ROE remains negative due to continuous net losses, which indicates profitability concerns.

Cash Flow

Free cash flow has been positive in the TTM period, showing signs of improvement. The operating cash flow to net income ratio is favorable, suggesting a good cash conversion from operations despite negative net income.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.57B	2.60B	2.41B	2.03B	1.09B
Gross Profit	1.82B	1.84B	1.66B	1.38B	703.13M
EBITDA	-587.01M	154.00M	-13.38B	-84.67M	-438.01M
Net Income	-1.00B	-220.37M	-13.66B	-428.79M	-485.14M
Balance Sheet
Total Assets	3.52B	4.39B	4.35B	17.73B	17.76B
Cash, Cash Equivalents and Short-Term Investments	1.30B	1.12B	918.18M	896.02M	786.57M
Total Debt	1.58B	1.59B	1.57B	1.27B	1.47B
Total Liabilities	2.03B	2.07B	2.04B	1.69B	1.87B
Stockholders Equity	1.49B	2.33B	2.31B	16.05B	15.88B
Cash Flow
Free Cash Flow	282.89M	193.67M	16.53M	130.06M	-79.55M
Operating Cash Flow	293.68M	350.02M	189.29M	193.99M	-53.51M
Investing Cash Flow	-124.05M	-156.35M	-167.74M	-72.98M	-590.98M
Financing Cash Flow	8.31M	10.85M	6.50M	40.95M	859.14M

Teladoc Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 8.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TDOC, the sentiment is Neutral. The current price of 8.04 is below the 20-day moving average (MA) of 8.17, above the 50-day MA of 7.55, and below the 200-day MA of 8.96, indicating a neutral trend. The MACD of 0.17 indicates Positive momentum. The RSI at 51.56 is Neutral, neither overbought nor oversold. The STOCH value of 21.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TDOC.

Teladoc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NHC	75 Outperform	$1.52B	14.28	11.19%	2.61%	19.16%	31.92%
PHR	71 Outperform	$1.61B	―	-15.97%	―	16.29%	66.01%
TDOC	56 Neutral	$1.38B	―	-54.49%	―	-2.54%	-322.03%
SDGR	55 Neutral	$1.56B	―	-43.33%	―	22.29%	-32.89%
ARQT	54 Neutral	$1.84B	―	-70.58%	―	100.03%	64.22%
Sector *	46 Neutral	C$197.02M	-3.33	-23.14%	2.65%	20.75%	-0.36%
ELVN	36 Underperform	$1.34B	―	-31.30%	―	―	12.85%

Teladoc Corporate Events

Teladoc Approves Key Proposals at Annual Meeting

On May 22, 2025, Teladoc Health, Inc. held its Annual Meeting of Stockholders, where several key proposals were approved. Notably, the stockholders approved an amendment to the 2023 Incentive Award Plan, increasing the number of shares available for issuance by 6,850,000. Additionally, the election of directors and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, were confirmed. These decisions are expected to impact the company’s strategic direction and operational governance.

The most recent analyst rating on (TDOC) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Teladoc stock, see the TDOC Stock Forecast page.